rheumatoid arthritis

FDA clears second Remicade biosimilarIn what is expected to produce hefty saving for rheumatoid arthritis patients and the healthcare system, FDA approved the second biosimilar to Remicade (Johnson & Johnson).
Potential blockbuster arthritis drug delayedCiting safety concerns, FDA delayed approval of a new blockbuster drug to treat rheumatoid arthritis.
Anakinra for RA and Refractory Idiopathic Recurrent Pericarditis
Anakinra for RA and Refractory Idiopathic Recurrent PericarditisCardiac Matters—What you need to know about anakinra
New strategies for managing drug spend: RA, Cancer, Hep C
New strategies for managing drug spend: RA, Cancer, Hep CThe proliferation of specialty drugs has prompted new techniques for keeping costs in tow.
Six diseases reap benefits of biomarkers, genetic tests
Six diseases reap benefits of biomarkers, genetic testsBiomarker testing for harmful genetic mutations provides the opportunity to identify at-risk individuals who might benefit from risk modification strategies and/or enhanced disease screening.
Protocols for High-Risk Pregnancies: Autoimmune DiseaseIn this protocol, Dr Lockwood reviews the pathophysiology, diagnosis, and management of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA).
Will new autoimmune drugs address cost concerns?Find out what’s in the drug pipeline for autoimmune disease.
Integrating pharmacy benefit, medical benefit cuts costsHere’s how one non-profit health plan harnessed the power of medical and pharmacy data to rein in drug costs.
Rheumatoid arthritis: Partnering for optimal care
Rheumatoid arthritis: Partnering for optimal careThe goal of this activity is to educate pharmacists and technicians in how best to assist patients in the use of medications used to treat rheumatoid arthritis.
Will docs prescribe the new RA biosimilars?While FDA recently approved two new biosimilars for rheumatoid arthritis and other inflammatory diseases, questions remain about how quickly physicians and patients will embrace the new drugs.